Feedback

The potential function and clinical application of FGF21 in metabolic diseases

Affiliation
Institute of Digestive Diseases ,Longhua Hospital ,Shanghai University of Traditional Chinese Medicine ,Shanghai ,China
Chen, Zhiwei;
Affiliation
Institute of Digestive Diseases ,Longhua Hospital ,Shanghai University of Traditional Chinese Medicine ,Shanghai ,China
Yang, Lili;
Affiliation
Teaching Experiment Center ,Shanghai University of Traditional Chinese Medicine ,Shanghai ,China
Liu, Yang;
Affiliation
Institute of Digestive Diseases ,Longhua Hospital ,Shanghai University of Traditional Chinese Medicine ,Shanghai ,China
Huang, Ping;
Affiliation
Institute of Digestive Diseases ,Longhua Hospital ,Shanghai University of Traditional Chinese Medicine ,Shanghai ,China
Song, Haiyan;
Affiliation
Institute of Digestive Diseases ,Longhua Hospital ,Shanghai University of Traditional Chinese Medicine ,Shanghai ,China
Zheng, Peiyong

As an endocrine hormone, fibroblast growth factor 21 (FGF21) plays a crucial role in regulating lipid, glucose, and energy metabolism. Endogenous FGF21 is generated by multiple cell types but acts on restricted effector tissues, including the brain, adipose tissue, liver, heart, and skeletal muscle. Intervention with FGF21 in rodents or non-human primates has shown significant pharmacological effects on a range of metabolic dysfunctions, including weight loss and improvement of hyperglycemia, hyperlipidemia, insulin resistance, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). Due to the poor pharmacokinetic and biophysical characteristics of native FGF21, long-acting FGF21 analogs and FGF21 receptor agonists have been developed for the treatment of metabolic dysfunction. Clinical trials of several FGF21-based drugs have been performed and shown good safety, tolerance, and efficacy. Here we review the actions of FGF21 and summarize the associated clinical trials in obesity, type 2 diabetes mellitus (T2DM), and NAFLD, to help understand and promote the development of efficient treatment for metabolic diseases via targeting FGF21.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Chen, Yang, Liu, Huang, Song and Zheng.

Use and reproduction: